Assembly Biosciences - 15 Year Stock Price History | ASMB
Historical daily share price chart and data for Assembly Biosciences since 2011 adjusted for splits and dividends. The latest closing stock price for Assembly Biosciences as of May 13, 2026 is 31.72.
- The all-time high Assembly Biosciences stock closing price was 1150.20 on May 13, 2011.
- The Assembly Biosciences 52-week high stock price is 39.71, which is 25.2% above the current share price.
- The Assembly Biosciences 52-week low stock price is 12.19, which is 61.6% below the current share price.
- The average Assembly Biosciences stock price for the last 52 weeks is 26.24.
| Assembly Biosciences Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 28.6593 | 33.7500 | 33.7500 | 25.3900 | 31.7200 | -6.73% |
| 2025 | 20.2711 | 17.1500 | 38.5000 | 8.2600 | 34.0100 | 115.53% |
| 2024 | 14.3409 | 9.9840 | 19.4300 | 9.5688 | 15.7800 | 60.35% |
| 2023 | 12.6612 | 16.0800 | 20.8800 | 7.7676 | 9.8412 | -36.92% |
| 2022 | 21.4465 | 29.4000 | 29.4000 | 13.0800 | 15.6000 | -44.21% |
| 2021 | 47.3995 | 72.4800 | 79.5600 | 25.5600 | 27.9600 | -61.49% |
| 2020 | 204.0138 | 238.8000 | 324.4800 | 58.4400 | 72.6000 | -70.43% |
| 2019 | 194.0036 | 276.4800 | 299.1600 | 100.3200 | 245.5200 | -9.55% |
| 2018 | 475.6879 | 555.3600 | 769.9200 | 228.6000 | 271.4400 | -50.01% |
| 2017 | 321.8113 | 146.2800 | 598.9200 | 146.2800 | 543.0000 | 272.43% |
| 2016 | 89.6583 | 86.2800 | 169.8000 | 54.4800 | 145.8000 | 61.78% |
| 2015 | 153.3181 | 94.5600 | 242.4000 | 87.8400 | 90.1200 | -4.45% |
| 2014 | 102.9797 | 225.6000 | 267.6000 | 51.6000 | 94.3200 | -58.85% |
| 2013 | 164.4384 | 143.4000 | 229.2000 | 123.0000 | 229.2000 | 76.85% |
| 2012 | 389.8670 | 479.4000 | 754.8000 | 123.6000 | 129.6000 | -73.03% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.451B | $0.072B |
| Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly's product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |